A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

Eligibility Criteria

• * Physician-diagnosed PAR.
• * Has a positive skin prick test (SPT) with indoor allergens and/or positive antigen-specific serum immunoglobulin E (IgE) for indoor allergens ≥0.70 kU/L, utilizing a validated assay (central laboratory).
• * A dermatographic participant who has a known history of dermatographism or identified during the SPT may participate in this study with a positive serum IgE test.
• * Participants who have concomitant asthma must be stable in the 3 months prior to screening using permitted regular asthma treatment.
• * Have received a dose of lebrikizumab.
• * Is currently on allergen immunotherapy. However, individuals who discontinued subcutaneous or sublingual immunotherapy (SCIT/SLIT) for ≥3 years prior to randomization are eligible, if they were not on a maintenance allergen immunotherapy (AIT) regimen.
• * Have received treatment with any rescue medication during the screening and/or run-in period.
• * Have received treatment with any biologic or systemic immunosuppressants for inflammatory disease or autoimmune disease prior to the baseline visit:
• 1. B cell-depleting biologics, including rituximab, within 6 months.
• 2. other biologics within 5 half-lives (if known) or 8 weeks, whichever is longer.
• 3. Systemic immunosuppressants within 4 weeks prior to baseline.
• * Have a history of seasonal worsening of AR and if the seasonal worsening is expected during the 4-week run-in period, the first 16 weeks after randomization, or during the last 4 weeks of the maintenance period.
• * Anticipates significant changes in their daily environmental exposure
• * Has a known history of recurrent acute or chronic sinusitis,
• * Female participant who is pregnant, breastfeeding or is planning to become pregnant or to breastfeed during the study.